However, many preclinical studies have demonstrated that when HDAC inhibitors are used in combination with mitogen-activated protein kinase (MAPK) inhibitors in RAS-mutated cancers, cell death occurs [17,18,31,32]. Here, HDAC9 is linked to cancer.